Tarsus Pharmaceuticals raises XDEMVY guidance after 69% sales surge
Tarsus Pharmaceuticals has posted second quarter 2026 net product sales of $173.9 million for XDEMVY, its lotilaner-based eye drop for Demodex blepharitis, representing a year-on-year increase of more than 69%. The NASDAQ-listed company raised its full-year 2026 XDEMVY revenue guidance to $685–$705 million, up from its prior range, citing strong prescriber adoption and the ongoing impact of its direct-to-consumer campaigns.
The quarterly gross margin held near-steady at 93%, down just one percentage point from the prior-year period, despite cost of sales doubling to $12.1 million as manufacturing royalties and licensor milestone amortisation scaled with revenue. The company reported a net loss of $18.6 million for the quarter, narrowed from $20.3 million in Q2 2025, and held cash, equivalents and marketable securities of $449.7 million as at 30 June 2026.
Alkeus acquisition and retina push
Alongside the financial results, Tarsus confirmed an agreement to acquire Alkeus Pharmaceuticals and its lead asset ALK-001, described in the release as an investigational once-daily oral small molecule designed to reduce toxic vitamin A dimer formation in the retina. The therapy is targeting the underlying biology of Stargardt disease, an inherited retinal condition the company says affects more than 36,000 patients in the United States and can progress to blindness. ALK-001 carries an active Phase 3 clinical programme, giving Tarsus an immediate late-stage asset in retina.
To fund the transaction, Tarsus priced a $125 million private placement, which the company said drew participation from top-tier funds and several existing Alkeus investors. The acquisition follows Tarsus's earlier purchase of iRenix Medical, which brought IRX-101, an investigational ocular antiseptic intended to reduce pain and corneal toxicity associated with intravitreal injections. Tarsus said a Phase 3 trial for IRX-101, designated COMFORT, is expected to initiate in the first half of 2027.
Chief executive Bobby Azamian said the commercial performance of XDEMVY gives the company the financial foundation "to remain intensely focused on growing XDEMVY while strategically investing in our next wave of growth."
Market context and competitive landscape
The Stargardt disease space has historically attracted limited late-stage activity given the small but well-defined patient population and the absence of approved treatments. ALK-001's Phase 3 status places Tarsus in a relatively uncrowded field, though a small number of other developers have pursued gene therapy and pharmacological approaches to inherited retinal dystrophies more broadly. Stargardt disease has received orphan drug designation in the United States and Europe, providing regulatory incentives including extended market exclusivity that will be relevant to Tarsus's commercial calculus.
More broadly, the ophthalmic pharmaceutical sector has seen consolidating interest from mid- and large-cap players. Tarsus, with a single approved product generating annualised revenues approaching $700 million and a growing pipeline spanning blepharitis, ocular rosacea, intravitreal antisepsis, Lyme disease prevention and now an inherited retinal dystrophy, is positioning itself as an independent multi-franchise eye care company rather than a single-asset acquiree. Investors will focus on whether the lotilaner platform can sustain pipeline delivery alongside the Alkeus integration, and on Phase 2 topline readouts for both TP-04 in ocular rosacea and TP-05 in Lyme disease prevention, both expected in the first half of 2027.